BioSpace News Archive

VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced the closing of a $150 million Series B financing.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced pipeline updates for 2021 and a research collaboration with MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb.

CND Life Sciences (cndlifesciences.com), an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, will participate in the 2021 virtual Biotech Showcase taking place during the 39th Annual J.P. Morgan Healthcare Conference (January 11-14, 2021).

Expanded In Vitro Modeling Tools Will Enable Researchers to Better Understand the Effects of Advanced Biologics and Gene Therapies

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference, being held on January 11-14, 2021.

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 3,650,840 shares of its common stock,

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 studies of DTX401, an investigational adeno-associated virus (AAV) gene therapy for Glycogen Storage Disease Type Ia (GSDIa), and DTX301,

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that Chairman and CEO Francois Michelon will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021

Funds expected to propel two lead radiopharmaceutical programs, VMT01 and VMT-

Economic activity in the hospital subsector grew in December for the seventh consecutive month, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.